Martin Eduardo Richardet

Author

Institut Gustave Roussy

Also Known As

M Richardet, M. E. Richardet, M. Richardet, Martin Eduardo Richardet, Martin Richardet, Martín Richardet

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Institut Gustave Roussy Instituto Oncológico de Córdoba Bristol-Myers Squibb (United States)Memorial Sloan Kettering Cancer Center Niigata University

About

Martin Eduardo Richardet is an author at Institut Gustave Roussy specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	644
2	Health Sciences	5	5	170
3	Pathology	3	3	108
4	Immunology	2	2	42
5	Diagnostic Sciences	1	1	31

Martin Eduardo Richardet

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma Toni K. Choueiri, Thomas Powles, Mauricio Burotto, New England Journal of Medicine	2021	1.6K
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial Robert J. Motzer, Bernard Escudier, Saby George, Cancer	2020	327
Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025 Bernard Escudier, Robert J. Motzer, Padmanee Sharma, European Urology Checkmate 025UrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2017	233
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial Martin Schüler, James Chih‐Hsin Yang, K. Park, Annals of Oncology	2015	131
696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Annals of Oncology UrologyGenitourinary CancerMedicinePharmacologyImmune Checkpoint Inhibitor	2020	116
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial Thomas Powles, Mauricio Burotto, Bernard Escudier, ESMO Open	2024	74
Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. Robert J. Motzer, Toni K. Choueiri, Thomas Powles, Journal of Clinical Oncology Cancer ManagementPathologySarcomatoid HistologyPharmacotherapyTumor Biology	2021	70
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism Albert Font, José Miguel Sánchez, Miquel Tarón, Investigational New Drugs UrologyOncogenic AgentMedicineHuman PolymorphismWeekly Regimen	2003	67
Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. Mauricio Burotto, Thomas Powles, Bernard Escudier, Journal of Clinical Oncology UrologyOncologyGenitourinary CancerImdc Risk ScoreMedicine	2023	46
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet, Journal for ImmunoTherapy of Cancer	2024	32

Page 1